About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Cleveland | 345 Studies

Clinical Trials LymphomaCleveland

Lymphoma Clinical Trials in Cleveland

Find 345 clinical trials for lymphoma near Cleveland, Ohio. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Cleveland

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 21-40 of 345 trials

CompletedSWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin LymphomaRATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.NCT01000558·Mobile, Alabama and 202 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedFirst-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasThe ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas.NCT03188965·Duarte, California and 28 others

Active not recruitingNKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersThis is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting…NCT05020678·Denver, Colorado and 5 others

CompletedStudy Evaluating CMC-544 In B-Cell Non-Hodgkin's LymphomaTo determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).NCT00073749·Birmingham, Alabama and 21 others

RecruitingA Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory…NCT06393738·New Haven, Connecticut and 20 others

CompletedPh I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLThe purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of…NCT00546793·Savannah, Georgia and 4 others

TerminatedEverolimus and Bortezomib in Treating Patients With Relapsed or Refractory LymphomaRATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.NCT00671112·Cleveland, Ohio

TerminatedStudy of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLA Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1…NCT05153330·Irvine, California and 40 others

CompletedDose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLThis is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of…NCT04030195·Duarte, California and 4 others

Not yet recruitingBAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic MalignanciesTherapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response…NCT07679919·Cleveland, Ohio

CompletedSafety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell LymphomasThis is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have…NCT02271945·Birmingham, Alabama and 5 others

CompletedA Study of Fibrocaps™ in Surgical BleedingThe purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, for achieving hemostasis.NCT01527357·Birmingham, Alabama and 47 others

CompletedPhase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCLThis is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab…NCT04134936·Tucson, Arizona and 69 others

Active not recruitingTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialThis phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced)…NCT04284774·Birmingham, Alabama and 171 others

TerminatedOral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's LymphomasRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00003113·Cleveland, Ohio

CompletedBlood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)Blood stem cell transplants are one treatment option for people with lymphoma or other types of blood cancers.NCT00912223·Duarte, California and 20 others

CompletedA Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisThe purpose of the study is to evaluate dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).NCT01959282·La Jolla, California and 96 others

RecruitingInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyThis phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute…NCT03959085·Birmingham, Alabama and 230 others

TerminatedStudy of IV CBL0137 in Previously Treated Hematological SubjectsThis clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics…NCT02931110·Whittier, California and 3 others

TerminatedO6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell LymphomaThis phase I trial is studying the side effects and best dose of carmustine given together with O(6)-benzylguanine in treating patients with stage I or stage II cutaneous T-cell…NCT00003613·Cleveland, Ohio

PreviousPage 2 of 18Next

Other Conditions in Cleveland

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia